Nuvectis says China regulator approves ciprocopan for treatment-naive PNH patients - NVCT News | RalliesNuvectis says China regulator approves ciprocopan for treatment-naive PNH patients
N
NVCT• China approves ciprocopan for treatment-naive PNH patients
- Nuvectis partner Haisco secured China NMPA marketing clearance for ciprocopan (NXP100) in treatment-naive paroxysmal nocturnal hemoglobinuria patients.
- Ciprocopan is the first once-daily oral complement Factor B inhibitor to win global approval.
- A separate China filing for PNH patients previously treated with anti-C5 therapies remains under NMPA review.
•
